What is REVOLADE?

REVOLADE is a thrombopoietin receptor agonist or TPO-RA with a targeted mechanism of action that increases platelet production without compromising the immune system^1–3

REVOLADE is a once-daily oral treatment for primary immune thrombocytopenia (ITP) patients aged 1 year and over who are refractory to other treatments. It is available as a film-coated tablet (FCT) or a powder for oral suspension (PfOS) for those who have trouble swallowing a tablet^1,2

What can REVOLADE offer your ITP patients?

Choose REVOLADE for your ITP patients with confidence

FCT, film-coated tablet; ITP, immune thrombocytopenia; PfOS, powder for oral suspension; TPO-RA, thrombopoietin receptor agonist.

*A total of 5541 subjects have been exposed to REVOLADE since the development international birthdate in October of 2004.⁹

References

1. REVOLADE FCT Summary of Product Characteristics.
2. REVOLADE PfOS Summary of Product Characteristics.
3. Kuter D. Int J Hematol. 2013;98:10–23.
4. Wong R, et al. Blood. 2017;130:2527–2536.
5. Cheng G, et al. Lancet. 2011;377:393–402.
6. Bussel J, et al. Br J Haematol. 2013;160:538–546.
7. Bussel J, et al. Lancet. 2015;2:315–325.
8. Grainger J, et al. Lancet. 2015;386:1649–1658.
9. Data on file REVDOFPATIENTYEARS.